BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11549432)

  • 1. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.
    van Agthoven M; Vellenga E; Fibbe WE; Kingma T; Uyl-de Groot CA
    Eur J Cancer; 2001 Sep; 37(14):1781-9. PubMed ID: 11549432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Majolino I; Pearce R; Taghipour G; Goldstone AH
    J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
    Vellenga E; van Agthoven M; Croockewit AJ; Verdonck LF; Wijermans PJ; van Oers MH; Volkers CP; van Imhoff GW; Kingma T; Uyl-de Groot CA; Fibbe WE
    Br J Haematol; 2001 Aug; 114(2):319-26. PubMed ID: 11529850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
    Bennett CL; Armitage JL; Armitage GO; Vose JM; Bierman PJ; Armitage JO; Anderson JR
    J Clin Oncol; 1995 Apr; 13(4):969-73. PubMed ID: 7707125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis of autologous peripheral stem cell transplantation versus autologous bone marrow transplantation for patients with non Hodgkin's lymphoma and acute lymphoblastic leukaemia.
    Jerjis S; Croockewit S; Muus P; Schaap N; Preijers F; de Witte T
    Leuk Lymphoma; 1999 Dec; 36(1-2):33-43. PubMed ID: 10613448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
    J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
    Sobecks RM; Le Beau MM; Anastasi J; Williams SF
    Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
    Messori A; Bonistalli L; Costantini M; Alterini R
    Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
    Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Demuynck HM; Link H; Zander A; Barge A
    Lancet; 1996 Feb; 347(8998):353-7. PubMed ID: 8598700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
    Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
    Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
    Uyl-de Groot CA; Hagenbeek A; Verdonck LF; Löwenberg B; Rutten FF
    Bone Marrow Transplant; 1995 Sep; 16(3):463-70. PubMed ID: 8535321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma.
    Uyl-de Groot CA; Ossenkoppele GJ; Buijt I; Huijgens PC
    Pharmacoeconomics; 1999 Mar; 15(3):305-11. PubMed ID: 10537437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
    Kessinger A; Nademanee A; Forman SJ; Armitage JO
    Hematol Oncol Clin North Am; 1990 Jun; 4(3):577-87. PubMed ID: 1972701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
    Uyl-de Groot CA; Ossenkoppele GJ; Buijt I; Huijgens PC
    J Hematother Stem Cell Res; 1999 Dec; 8(6):619-25. PubMed ID: 10645769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
    Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
    Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalated total body irradiation and autologous stem cell transplantation for refractory hematologic malignancy.
    McAfee SL; Powell SN; Colby C; Spitzer TR
    Int J Radiat Oncol Biol Phys; 2002 May; 53(1):151-6. PubMed ID: 12007954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.